Thursday, 2 March 2017

Persistent Facial Erythema Treatment Market: Future market projections for forthcoming years

Persistent facial erythema is a redness of the facial skin and mostly noticeable in individuals with fair skin. The facial redness occurs due to dilation of cutaneous blood vessel and increased blood flow to the skin. Persistent facial erythema often goes undiagnosed among dark-skinned individuals. Facial erythema are caused due to several factors, including primary skin diseases such as rosacea and perioral dermatitis, and systemic illnesses. Facial erythema is characterized by burning skin, itching, dry skin, flushing, visible blood vessels, and pain. Rosacea affects millions of people worldwide and is a common chronic facial skin disease with female predominance, mostly those with fair skin. This skin disease typically affects the convexities of the central face. Erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, and ocular rosacea are the four types of this skin disease. Each type of rosacea has different characteristics and the treatment depends on the severity of the lesion. According to AZoNetwork, a leading health care, life science online publisher in the U.K., the prevalence rate of rosacea is 1.65 per 1,000 person every year.
Factors such as large patient population, new product launch, increase in smoking, growth in consumption of alcohol, large pipeline drugs, and climatic change are projected to drive the global persistent facial erythema treatment market. According to the United Nations Population Fund (UNFPA), the human population worldwide is growing at a rate of 1.1%. Technological advancement and rapid rise in population are other factors which are expected to fuel the growth of the global market during the forecast period. However, generic competition and stringent regulations for product approvals are hindrances which are anticipated to restrict the market growth.
The global persistent facial erythema treatment market has been segmented by drug type, disease type, distribution channel, and geography. In terms of drug type, the market is classified into emollients, antihistamines, antifungal, antibiotics, corticosteroids, and calcineurin inhibitors. In terms of disease type, the market is classified into seborrhea, eczema, rosacea, acne, lupus, and tinea. In terms of distribution channel, the market is classified into hospitals pharmacies, retail pharmacies, and online pharmacies
In terms of geography, the market is distributed over North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Geographically, North America dominates the market owing to early treatment adoption, lifestyle changes, and new product innovation. These factors are projected to drive the market growth. A significant proportion of the U.S. population has symptoms of eczema. According to the National Eczema Association in the U.S., 31.6 million people are living with eczema and prevalence rate of childhood eczema is 10.7%. Europe is the second leading market for persistent facial erythema treatment market due to large research and development activities and increase in consumption of alcohol. In the next few years, the market in Asia Pacific is expected to grow at a higher rate due to larger target patient pool, changing lifestyle, rapid population growth, adoption of western lifestyle, and increase in research and development. The Latin America and Middle East & Africa markets are estimated to create a large opportunity for persistent facial erythema treatment due to climatic change, increase in importance of skin care, rise in consumption of alcohol which causes skin diseases, and growth in investment of key manufacturers. According to the Institute of Alcohol Studies, the worldwide average consumption of pure alcohol per adult is of 6.2 liter/year. In Brazil, the average is 8.7 liter/year.
The major players operating in this market include Astellas Pharma Inc., Sanofi S.A., Valeant Pharmaceuticals International, Inc., Novartis International AG, Pfizer Inc., Meda Pharmaceuticals, Regeneron Pharmaceuticals Inc., Galderma S.A., and Anacor Pharmaceuticals Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Posted by at No comments:
Labels:

Addison’s Disease Treatment Market: New Market Research Report Announced; Global Industry Analysis 2016 - 2024

Addison's disease is characterized by an uncommon disorder with insufficient production of the steroid hormones known as aldosterone and cortisol from the cells of adrenal glands. Moreover, indications of Addison's disease are known as primary adrenal insufficiency, resulting from insufficient production of two hormones cortisol and aldosterone. Symptoms associated with Addison’s disease include gastrointestinal abnormalities, fatigue, and changes in skin color. Furthermore, mood changes and behavior may occur in some individuals with Addison's disease. The need for treatment of Addison’s disease is growing due to rising prevalence of disease, increasing income in developed economies, and growing awareness. Furthermore, rising health expenditure is propelling the global market. Currently, the U.S. and EU5 countries are the key markets for Addison’s disease treatment, where the well-being of life with symptoms that are tough to manage have become controllable. The Addison’s disease treatment market is expected to expand at a high growth rate during the forecast period. Moreover, lack of proper diagnosis acts as a restraint of the market, especially in developing countries.
Addison’s disease requires lifelong treatment with steroid replacement therapy. Glucocorticoid and mineralocorticoid replacement therapy is currently most widely used for the treatment of Addison's disease. Additional, hydrocortisone is one of the most preferred drugs belonging to the glucocorticoid class due to its short half-life which enables it to be quickly absorbed into the blood stream. Furthermore, long acting glucocorticoids such as dexamethasone and prednisone are beneficial for once daily dosing schedule. These do not replicate the physiological daily rhythm of endogenous cortisol production in the body, which results in excess glucocorticoid levels overnight. Rarely prescribed fludrocortisone belongs to the mineralocorticoid class and is frequently prescribed along with hydrocortisone.
The Addison’s disease treatment market can be segmented based on type of drug class, distribution channel, and region. In terms of drug class, the Addison’s disease treatment can be categorized into glucocorticoid and mineralocorticoid. Glucocorticoid can be categorized into hydrocortisone, dexamethasone, and prednisone. The mineralocorticoid segment can be sub-segmented into fludrocortisone. Based on distribution channel, the market can be segmented into hospital pharmacy, retail pharmacy, and e-commerce.
In terms of region, the Addison’s disease treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America was the largest market for Addison’s disease treatment owing to high concerns for human health and growing awareness. Additionally, the U.S. and Canada have been successfully utilizing Addison’s disease treatment. This is likely to boost the growth of the market in the region. Presence of well-established health care infrastructure, government initiatives in implementing Addison’s disease treatment, and constantly improving reimbursement scenario is projected to propel the market in North America. Europe was the second largest market for Addison’s disease treatment owing to enhanced health processes and implementation of high health care concerns in the region.
Asia Pacific is expected to be the fastest growing market for Addison’s disease treatment. Major factors expected drive the Addison’s disease treatment market in the region are the large population and growing awareness about health, especially in India and China. Additionally, China and India are the top emerging markets in the region and would increasingly contribute to the growth of the Addison’s disease treatment. In Latin America, Brazil and Mexico are the countries that have significant potential for growth due to developing medical organization structure and rising disposable incomes.
Key players operating in the global Addison’s disease treatment market include Pfizer Inc., Boehringer Ingelheim GmbH, ViroPharma, Tocris Bioscience, GlaxoSmithKline plc, Merck KGaA, and Lupin Pharmaceuticals, Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Posted by at 1 comment:
Labels:

Wednesday, 1 March 2017

Breast Pumps Market: Detailed analysis and profiling of additional market players

Breast pumps refer to the medical devices regulated by the U.S. Food and Drug Administration (FDA) used by the lactating mothers to ensure uninterrupted milk supply to their infants when away from home. Breast pumps based on the mode of operation are classified into four major types namely manual, single electric, double electric and hospital grade breast pumps. Based on the design, there are two main types of breast pumps available; closed and open systems. Open systems do not contain a barrier between the milk collection kit and the pump tubing due to which collected milk is susceptible to contamination, while closed pumps prevent contamination due to the presence of a barrier between the collection kit and pump tubing. Currently, majority of the breast pumps available represent closed systems. Changing lifestyles and increasing number of women prioritizing their career along with their child, have emerged as the major factors impacting the growth of this market. On the other hand, high cost of the devices followed by risk of contamination might limit the market growth. Increasing disposable incomes of respective nations will further propel the market growth.
Recommendation of breast pumps is majorly dependent on the frequency of breastfeeding; Double electric breast pumps are the most preferred pumps for frequent breastfeeding as it ensures efficient milk expression with less time consumption. While single electric breast pumps are the most preferred pumps over manual pumps owing to powerful motor capacity and variable suction pressures. Hospital grade breast pumps are usually recommended in the initial phase of breastfeeding mainly to establish milk supply and get acquainted with the use of pumps. These pumps are by far the most superior types of breast pumps due to powerful motor, effective pumping capacity and can support multiple users. Distribution channel of personal grade breast pumps varies from hospital grade breast pumps; durable medical equipment (DME) supplier or retailer or online sales channel forms the base of personal grade breast pumps, while hospital grade pumps reaches to the end users via hospitals. Electric breast pumps are preferred over manual breast pumps due to several beneficial features such as electric motor support, effective milk expression and less time consumption.
The global market for breast pumps is analyzed from two perspectives; product type and geography. Manual, single electric, double electric and hospital grade breast pumps are the four major product types. Single electric breast pumps market is the largest market in 2013 owing to the reasonable price and several benefits over the manual pumps. In terms of volume, manual breast pumps constitute the leading market segment owing to its low cost and easy availability. Double electric breast pumps market segment is anticipated to be the fastest growing segment owing to best option available after hospital grade breast pumps. This is attributed to certain features such as easy and efficient milk expression solution for mothers who have to express milk several times a day and on a daily basis. In addition, these pumps are available with adjustable suction cycles; they start with shorter but quicker sucks in order to accelerate the letdown response, followed by longer, deeper and slower sucks.
Geographically, breast pumps market is studied for four regions: North America, Europe, Asia Pacific and Rest of the World. These regions are further analyzed by country. In terms of Revenue, North America accounted for the largest market share in 2013, owing to increasing breastfeeding rates and increasing awareness about breastfeeding. In terms of volume, North America leads the breast pumps market. Key players operating in the global breast pumps market include Medela AG, Ameda AG, Pigeon Corporation, Royal Philips Electronics NV, NUK USA LLC and Lansinoh Laboratories, Inc.
Posted by at No comments:
Labels:

Technological Advancements in Medical Research Growing Auto-Injectors Market

Auto-injectors are hypodermic syringes used to administer a single dose of a drug (typically any life saving drug). These are easy to use and are intended either for self-administration or by untrained personnel. The commercially available auto-injectors are majorly used for the management of anaphylaxis, multiple sclerosis and rheumatoid arthritis. High prevalence of anaphylaxis and food allergies is the major factor propelling the growth of the global auto-injectors market. According to the European Academy of Allergy and Clinical Immunology (EAACI), there has been a seven-fold increase in anaphylaxis related hospital admissions in Europe from 2003 to 2013. Similarly, the Australasian Society of Clinical Immunology and Allergy (ASCIA) stated that the number of anaphylaxis associated hospital admissions increased five times from 2004 to 2014 in New Zealand and Australia. Rising prevalence of anaphylaxis and food allergies is increasing the demand for epinephrine auto-injectors used for anaphylaxis management. Moreover, Healthline Networks, a provider of health information and technology solutions for advertisers, publishers, employers, and health plans and healthcare providers, stated that 2.5 million people were suffering from multiple sclerosis in 2013 worldwide. High prevalence of multiple sclerosis and rheumatoid arthritis is increasing the demand for novel treatment options among the patients, which in turn drives demand for auto-injectors globally.
Based on product types, the global auto-injectors market has been categorized into prefilled auto-injectors and fillable auto-injectors. Prefilled auto-injectors dominate the auto-injectors market due to their offered ease-of-use and rising patient awareness. Based on Therapeutic Applications, the global auto-injectors market has been segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis and others. The anaphylaxis segment was the leading and fastest growing market majorly due to high prevalence of the disease, rising awareness about epinephrine auto-injectors and advantages of its use for anaphylaxis management during emergency situations. Based on the manufacturing design, the auto-injectors market has been segmented into standardized auto-injectors and customized auto-injectors. Standardized auto-injectors dominated the market in 2013, as these are the oldest and most preferred auto-injectors with an established record of effective results. However, customized auto-injectors is estimated to be the fastest growing segment, as these offer customization of the dosage of the drug according to age, sex and need of the patient.
Geographically, the global auto-injectors market has been segmented into four major regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). North America dominated the global auto-injectors market in 2013 due to high prevalence of anaphylaxis, favorable government reimbursement policies and economic stability to purchase expensive auto-injectors in the region. On the other hand, Asia Pacific is estimated to be the most promising market for auto-injectors during the forecast period due to rising prevalence of anaphylaxis and multiple sclerosis in New Zealand and Australia coupled with the government reimbursement options in New Zealand, and rising awareness about novel treatment methods available in the market.
The auto-injectors market is consolidated and dominated by a few market players. Mylan, Inc. and Sanofi led the standardized auto-injectors segment due to higher demand for EpiPen and Auvi-Q auto-injectors, respectively. However, the SHL Group dominated the customized auto-injectors segment, with a wide product offering of prefilled customized auto-injectors. The other major companies operating in the auto-injectors market include Antares Pharma, Inc., Becton, Dickinson and Company, Biogen Idec, Inc., Novartis International AG, Pfizer, Inc., Unilife Corporation and Ypsomed Holdings AG. The auto-injectors market is innovation driven, therefore market players are constantly engaged in research and development activities in order to develop new and effective auto-injectors against various diseases.
Posted by at No comments:
Labels:

Steady Growth for Remote Patient Monitoring Market predicted through 2020

Remote patient monitoring is an emerging healthcare solution that enables monitoring of patients who are away from hospital settings. Remote patient monitoring offers several advantages such as reduction in hospital visits, data recording for prolong period, quick and accurate results, reduced cost for patients and assistance to medical practitioner with historic patient data. In addition, remote patient monitoring also reduces the waiting time in hospitals and enables medical practitioners to access the patient records from multiple places. Furthermore, growing demand for electronic health record (EHR) is fueling the demand for remote patient monitoring devices since these devices offer integration with cloud data bases for data storage and access. Growing patient population, rising awareness of lifestyle disorders and technological developments in medical devices have accentuated the growth of remote patient monitoring devices market.
Heart monitors, breath monitors, physical activity monitors, hematology monitors, body temperature monitors, multi-sign monitors and others are some of the remote monitoring devices that are widely used. Rising incidences of chronic diseases that require continuous monitoring such as diabetes, blood pressure and cardiovascular conditions, propels the demand for medical devices. In 2013, heart rate monitors segment dominated the global remote patient monitoring devices owing to high demand for these devices mainly due to rising prevalence of cardiac diseases. Furthermore, rising geriatric population propels the prevalence of cardiac diseases globally. Thus, owing to increasing number of patients diagnosed with cardiac diseases accentuates the uptake the heart rate monitors.
In 2013, ambulatory care centers segment accounted for the largest share in the global remote patient monitoring devices market. Growing geriatric population is primarily driving the demand for ambulatory care centers, as elderly people are at a higher risk of acquiring diseases and infections. However, rise in demand for home-based treatment as more number of patients opts for diagnosis and treatment of diseases at home boosts the home healthcare segment during the forecast period from 2014 to 2020.
Geographically, North America contributed the largest share in the global remote patient monitoring devices market. Increasing incidences of cardiovascular and respiratory diseases coupled with rising preference to reduce hospital readmissions. Under the Hospital Readmissions Reduction Program created by the Patient Protection and Affordable Care Act, government of the U.S. has imposed penalty to hospitals. As a penalty government has announced reduction up to 1% in the Medicare payment per patient for hospital readmission within 30 days in 2013. Thus, to reduce the hospital readmissions, medical professionals are promoting remote patient monitoring in the region.
The global remote patient monitoring devices market is a fragmented market with many local players competing with global players. In addition, presence of all the necessary resources is enabling easy entry of medical device manufacturers into the remote patient monitoring devices market. Thus, major players in the market are strategically collaborating with local players to offer innovative technologies and thereby sustain in the competition. In November 2014, LifeWatch AG partnered with Vital Connect, Inc., a health care company based in Silicon Valley. This collaboration enables LifeWatch to utilize Vital Connect’s HealthPatch MD as 1-lead ECG device in LifeWatch’s cardiac monitoring business. LifeWatch aims to expand its cardiac monitoring devices business by adding patch technology to its product offerings. Similarly, in December 2014, Omron Healthcare Inc. collaborated with AliveCor, Inc., a California-based company that provides mobile technology for heart health. The two companies aim to improve access to remote patient monitoring products through retail and online channels, especially for heart patients.
Posted by at No comments:
Labels:

Life Science Microscopy Devices Market size and Key Trends in terms of volume and value 2014-2020

Microscopy devices have paved the way for innovation in life science through their most potential feature — imaging minute details of any matter. Researchers are able to obtain images of neurons, synapses, cell structure and its processes of high quality using advanced microscopes. Microscopes are also used extensively in academic institutes for primary research. However, the demand for different types of microscopes varies based on the sample type and objective of study. For instance, optical microscopes are used for basic life science research in academic institutes, and private and public research laboratories. Additionally, price of a microscope plays an important role in determining demand, as emerging economies face funding issues. With improving technology, optical microscopes are being increasingly used for advanced life science research. Fluorescence and phase contrast microscopes are realizing their potential extensively in cell biology, pathology and toxicology studies. On the other hand, the use of electron and scanning probe microscopes is rapidly growing with the advancement in the research objectives.
The global life science microscopy devices market has been analyzed based on product type and geography. Three major types of microcopy devices are used in life science research: optical microscope, electron microscope and scanning probe microscope. Optical microscopes are extensively used in life science research because they cost less and address the primary objectives of researchers in academic institutes, and private and public research laboratories. The optical microscopes segment has been sub-segmented based on geography, applications and product type. Cell biology dominated the optical microscopes segment because of their light microscopy features that support cell biology research at minimal cost and effort over other life science applications. Stereo microscopes are the most commonly used optical microscopes in life science research across the world due to their low cost and the ability to generate three-dimensional perspective of the sample under study. However, demand for fluorescence microscopes is increasing rapidly, as staining techniques are being widely used in life science research. On the other hand, phase contrast microscopes are expected to replace fluorescence microscopes in the near future due to their ease of sample preparation and better image capturing features.
Electron microscopes offer high-resolution and magnification power up to 10 million times, which makes them appropriate for the visualization of three-dimensional structures of cells and tissues, determining the spatial arrangement of protein structures and the pathology of disease conditions. The electron microscopes segment has been sub-segmented into transmission electron microscope (TEM) and scanning electron microscope (SEM). The scanning electron microscope segment held the largest share of the global life science electron microscopy devices segment due to low cost and the capability to provide data on taxonomic and systemic parasite studies. However, the demand for transmission electron microscopes, which is an established technique used in cell biology applications, is increasing. Moreover, their use in neuroscience and biomedical engineering is growing rapidly, as researchers gain more interest in the study of brain activity.
The scanning electron microscopes segment has been sub-segmented into atomic force microscope and scanning tunneling microscope. Ease in sample preparation and better imaging is driving the demand for atomic force microscopes. Microscope manufacturers and researchers find these microscopes more useful in neuroscience, biomedical engineering and toxicology studies, as they can be used in vacuum, air, and water. Moreover, electron and scanning probe microscopes find wide applications in neuroscience, as these advanced microscopes offer atomic level imaging of brain sections.
Geographically, North America accounted for the largest share of the global life science microscopy devices market in 2013. However, demand for microscopy devices in Asia Pacific and Latin America is expected to be high during the forecast period due to the growing contract research organization (CRO) market in these regions.
The global life science microscopy devices market is characterized by the presence of few prominent players such as Nikon Corporation, FEI, JEOL Ltd., Leica Microsystems, Hitachi High-technology Corporation, Olympus Corporation, and Carl Zeiss AG.
Posted by at No comments:
Labels:

Infection Surveillance Solutions Market: Show Highest Growth Potential

Global Infection Surveillance Solutions Market: Snapshot
The demand for infection surveillance has been on the rise as the need to curb hospital-acquired infections and other epidemics is intensifying. Infection surveillance solutions are designed to continuously monitor and interpret data related to health in order to ensure accurate implementation of preventive measures. Hospital-acquired infections are also called as nosocomial infections, which are a result of poor hygienic conditions, negligence, decreased immunity of the patient, invasion of drug-resistant bacteria, and procedures that can weaken the effect of ongoing medications.
The commonly seen hospital-acquired infections amongst patients are lower respiratory tract infections, surgical wound infections, and urinary tract infections among others. Admission of geriatrics, who have a poor immune system, and patients who are already suffering from other medical conditions. The research report by Transparency Market Research has been collated using efficient research methodologies. The publication has carefully and meticulously curated valuable information to present to its readers.
Global Infection Surveillance Solutions Market: Segmentation
The products in the global infection surveillance solutions market are sold as services or software. The demand for software is higher than services due to technological advancement it offers for efficient management of patient data, its analysis, and interpretation. The software segment is further sub-segmented into on-premise software and web-based software. The services segment of the global infection surveillance solution market is further sub-segmented into consultation and training programs, product maintenance and support, and implementation of services.
The key end users of infection surveillance solutions are healthcare facilities and hospitals. Hospitals, which include small hospitals and large hospitals, are expected to dominate the global market in the coming years due to the high rate of admission of patients, increasing infections, and rise in the duration of patients staying at the hospitals are expected to augment the demand for infection surveillance solutions in hospitals across the globe in the coming years. The uptake of these solutions will also remain steady in nursing homes, nursing facilities, and other health care living facilities where patients are admitted for long-term care.
Global Infection Surveillance Solutions Market: Regional Outlook
Geographically, the global infection surveillance solutions market is divided into Latin America, North America, Asia Pacific, Europe, and the Middle East and Africa. The report indicates that Europe and North America have a strong foothold in the global market due to better healthcare facilities and reliable structure of reimbursement policies. The higher awareness of patients about better healthcare services is also expected to fuel the demand for infection surveillance solutions in the aforementioned regions in the coming years.
Asia Pacific is also expected to present lucrative opportunities to the global market in the coming years. The increasing efforts to avert hospital-acquired infections and to improve overall healthcare are projected to play a crucial role in determining the future of the Asia Pacific infection surveillance solutions market. The emergence of medical tourism in the region is also expected to drive the growth of this market in Asia Pacific in the coming years.
Key Players Mentioned in this Report are:
The research report includes as an assessment of prominent players operating in the global market. Some of the leading players making their market in the global infection surveillance solutions market are ICNet International Limited, Atlas Medical Software, Becton, Dickinson and Company, Premier, Inc., RL Solutions, Gojo Industries, Inc., Truven Health Analytics, and Hygreen, Inc. among others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)